Laboratoire Alphabio, 23 Rue de Friedland, 13006 Marseille, France.
Arch Virol. 2013 Jun;158(6):1143-9. doi: 10.1007/s00705-012-1584-4. Epub 2013 Jan 9.
A new genotyping-based DNA assay (Digene LQ(®)) was developed recently. The primary aim was to assess the distribution of HPV types using this new assay in atypical squamous cells of undeterminate significance (ASCUS). The secondary aim was to correlate the HPV types with the severity of the disease. The study population comprised 376 ASCUS women. The women were all Hybrid Capture II (HCII) positive and were admitted in three European referral gynecology clinics between 2007 and 2010. A colposcopy with histological examination was performed in all these patients. HPV 16 was typed in 40 % of patients, HPV 18 in 7 %, and HPV 31 in 17 %, and 18 % of patients had mixed genotypes. Patients aged over 30 more often had the HPV 16 genotype than patients aged under 30 (29 % vs. 11 %, chi-square test p < 0.001). The risk of cervical intra-epithelial neoplasia of grade 2 or more (CIN2 +) when HPV 18 positive is lower than the probability associated with HPV 16 or HPV 31: 28 % vs. 58 % and 52 %, respectively (chi-square test, p = 0.005 and p = 0.05, respectively). The Digene LQ(®), a new sequence-specific hybrid capture sample preparation, is fast and efficient and allows high-throughput genotyping of 18 HR HPV types by PCR compared to traditional non-sequence-specific sample preparation methods.
最近开发了一种基于基因分型的 DNA 检测方法（Digene LQ(®)）。主要目的是使用这种新方法评估 HPV 类型在非典型鳞状细胞意义不明确（ASCUS）中的分布。次要目的是将 HPV 类型与疾病的严重程度相关联。研究人群包括 376 名 ASCUS 女性。所有女性均为 Hybrid Capture II (HCII) 阳性，并于 2007 年至 2010 年间在欧洲三家转诊妇科诊所就诊。所有患者均行阴道镜检查及组织学检查。40%的患者 HPV 16 型阳性，7%的患者 HPV 18 型阳性，17%的患者 HPV 31 型阳性，18%的患者为混合基因型。30 岁以上的患者 HPV 16 基因型的发生率高于 30 岁以下的患者（29%对 11%，卡方检验 p<0.001）。HPV 18 阳性时，宫颈上皮内瘤变 2 级或更高级别（CIN2+）的风险低于 HPV 16 或 HPV 31 相关的概率：分别为 28%对 58%和 52%（卡方检验，p=0.005 和 p=0.05）。与传统的非序列特异性样本制备方法相比，Digene LQ(®)是一种快速有效的新的序列特异性杂交捕获样本制备方法，通过 PCR 可高通量地对 18 种高危 HPV 类型进行基因分型。
